A Randomized Double Blinded and Placebo-Controlled Trial to Assess the Impact of Biophoton Therapy on Self-Grown Stem Cells

Description

Study Objective The purpose of this clinical study is to evaluate if biophoton therapy, delivered by Tesla BioHealing® Biophoton Generators (Biophotonizer), can increase self-grown stem cells naturally. Study Design This is a randomized, double-blinded, placebo-controlled intervention clinical study to assess the effectiveness of biophoton therapy in impacting stem cells. Approximately 46 volunteers who want to increase self-grown stem cells will participate in the study. Study Randomization The biostatistician will prepare a randomization schedule including a serial of subject numbers. A subject number will be randomly assigned to each study participant, which will assign them to either the control group or the treatment group. Other than the Informed Consent Form (ICF), all study information will be recorded by using the subject number. The Principal Investigator, study physicians, study nurse, data-entry specialists, and biostatisticians, as well as the participants, will be blinded about who received which product during the first two weeks of study participation.

Conditions

Increase the Total Number of Stem Cells, Inflammation

Study Overview

Study Details

Study overview

Study Objective The purpose of this clinical study is to evaluate if biophoton therapy, delivered by Tesla BioHealing® Biophoton Generators (Biophotonizer), can increase self-grown stem cells naturally. Study Design This is a randomized, double-blinded, placebo-controlled intervention clinical study to assess the effectiveness of biophoton therapy in impacting stem cells. Approximately 46 volunteers who want to increase self-grown stem cells will participate in the study. Study Randomization The biostatistician will prepare a randomization schedule including a serial of subject numbers. A subject number will be randomly assigned to each study participant, which will assign them to either the control group or the treatment group. Other than the Informed Consent Form (ICF), all study information will be recorded by using the subject number. The Principal Investigator, study physicians, study nurse, data-entry specialists, and biostatisticians, as well as the participants, will be blinded about who received which product during the first two weeks of study participation.

A Randomized Double Blinded and Placebo-Controlled Trial to Assess the Impact of Biophoton Therapy on Self-Grown Stem Cells

A Randomized Double Blinded and Placebo-Controlled Trial to Assess the Impact of Biophoton Therapy on Self-Grown Stem Cells

Condition
Increase the Total Number of Stem Cells
Intervention / Treatment

-

Contacts and Locations

Tampa

Tesla MedBed at Tampa-FL, Tampa, Florida, United States, 33614

Butler

Tesla BioHealing Wellness Hotel - Butler-PA, Butler, Pennsylvania, United States, 16001

Participation Criteria

Researchers look for people who fit a certain description, called eligibility criteria. Some examples of these criteria are a person's general health condition or prior treatments.

For general information about clinical research, read Learn About Studies.

Eligibility Criteria

  • * Willing and able to give informed consent for participation in the trial.
  • * Is able and willing to comply with all trial requirements.
  • * Male or female ages 18-70 years old without major diseases.
  • * Participants must not be heavy users of Tesla BioHealing devices; enrollment will be determined by the clinical team based on an evaluation of the participant's prior device usage.
  • * Must be fluent in English.
  • * Untreated psychiatric disturbances that would affect trial participation as judged by the research medical professional.
  • * Is participating in another investigational drug or device trial
  • * Had been treated with Stem Cell therapy within a 6-month period.

Ages Eligible for Study

18 Years to 70 Years

Sexes Eligible for Study

ALL

Accepts Healthy Volunteers

No

Collaborators and Investigators

First Institute of All Medicines,

James Z Liu, MD, PhD, STUDY_CHAIR, First Institute of All Medicines

Study Record Dates

2026-03-30